Recruitment

Recruitment Status
Unknown status

Inclusion Criteria

Patients on thrice-weekly standard hemodialysis for > 3 months
Patients with a vascular access capable of delivering consistently a high blood flow rates ( ≥ 300 mL/min)
Patients willing to provide written informed consent.
Patients on thrice-weekly standard hemodialysis for > 3 months
Patients with a vascular access capable of delivering consistently a high blood flow rates ( ≥ 300 mL/min)
Patients willing to provide written informed consent.

Exclusion Criteria

Patients with any uncontrolled malignant disease
Patients considered by investigator to have difficulty in participation
Patients with active infectious or uncontrolled inflammatory disorders
...
Patients with any uncontrolled malignant disease
Patients considered by investigator to have difficulty in participation
Patients with active infectious or uncontrolled inflammatory disorders
Patients whose life expectancy < 12 months
Patients with recent major cardiovascular disease during the last 6 months
Patients who are likely to receive kidney transplant within the following 1 year

Summary

Conditions
  • End Stage Renal Disease
  • End-stage Renal Disease
Type
Interventional
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 20 years and 75 years
Gender
Both males and females

Inclusion Criteria

Patients on thrice-weekly standard hemodialysis for > 3 months
Patients with a vascular access capable of delivering consistently a high blood flow rates ( ≥ 300 mL/min)
Patients willing to provide written informed consent.
Patients on thrice-weekly standard hemodialysis for > 3 months
Patients with a vascular access capable of delivering consistently a high blood flow rates ( ≥ 300 mL/min)
Patients willing to provide written informed consent.

Exclusion Criteria

Patients with any uncontrolled malignant disease
Patients considered by investigator to have difficulty in participation
Patients with active infectious or uncontrolled inflammatory disorders
...
Patients with any uncontrolled malignant disease
Patients considered by investigator to have difficulty in participation
Patients with active infectious or uncontrolled inflammatory disorders
Patients whose life expectancy < 12 months
Patients with recent major cardiovascular disease during the last 6 months
Patients who are likely to receive kidney transplant within the following 1 year

Tracking Information

NCT #
NCT02092194
Collaborators
Boryung Pharmaceutical Co., Ltd
Investigators
Study Director: Won-Yong Cho, MD Korea University